AAPL 250.9362 1.1636% MSFT 439.85 0.5624% NVDA 132.26 2.5987% GOOGL 190.36 1.0403% GOOG 191.585 0.7547% AMZN 224.7026 1.8967% META 605.1 1.3245% AVGO 221.57 -0.9167% TSLA 434.8 -1.211% TSM 195.3 -0.133% LLY 758.87 -0.7637% V 315.9 1.9756% JPM 234.325 1.7168% UNH 493.79 -1.1867% NVO 103.7 -2.1329% WMT 93.89 0.3634% LVMUY 130.52 0.7721% XOM 105.67 -0.7048% LVMHF 649.5 0.6649% MA 526.755 1.3068%
Last update at 2024-12-19T18:52:00Z
Genmab A/S (GMAB): Leading Innovation in Antibody Therapeutics
Thu 17 Oct 24, 12:57 PMIs the Options Market Predicting a Spike in Genmab (GMAB) Stock?
Wed 16 Oct 24, 01:44 PMIs Genmab (GMAB) Stock Undervalued Right Now?
Tue 15 Oct 24, 01:40 PMGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
Tue 15 Oct 24, 10:25 AMGenmab A/S (GMAB): Among The Stocks With Biggest Upside Potential According to Hedge Funds
Wed 09 Oct 24, 07:32 PMGMAB or INCY: Which Is the Better Value Stock Right Now?
Tue 08 Oct 24, 03:40 PMDown -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
Tue 08 Oct 24, 01:35 PMIs Genmab A/S (GMAB) One of the Best Revenue Growth Stocks to Buy According to Analysts?
Mon 30 Sep 24, 04:40 PMGrant of Restricted Stock Units and Warrants to Employees in Genmab
Thu 26 Sep 24, 07:17 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
| Minority interest | - | - | - | 0.00000M | 0.00000M |
| Net income | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
| Selling general administrative | 2676.00M | 1283.00M | 661.00M | 342.00M | 213.69M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
| Reconciled depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
| Ebit | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1612.39M |
| Ebitda | 7043.00M | 3463.00M | 6756.00M | 2897.00M | 1699.98M |
| Depreciation and amortization | 686.00M | 445.00M | 443.00M | 259.00M | 87.60M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 6357.00M | 3018.00M | 6313.00M | 2638.00M | 1380.28M |
| Other operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
| Interest expense | 21.00M | 13.00M | 10.00M | 7.00M | 0.42M |
| Tax provision | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
| Interest income | 324.00M | 197.00M | 184.00M | 348.00M | 62.92M |
| Net interest income | 303.00M | 184.00M | 174.00M | 334.00M | 62.51M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 1513.00M | 975.00M | 1146.00M | 693.00M | 139.83M |
| Total revenue | 14595.00M | 8482.00M | 10111.00M | 5366.00M | 3025.14M |
| Total operating expenses | 8238.00M | 5464.00M | 3798.00M | 2728.00M | 1644.85M |
| Cost of revenue | - | - | - | 0.00000M | 0.00000M |
| Total other income expense net | 678.00M | 965.00M | -409.00000M | 221.00M | 231.69M |
| Discontinued operations | - | - | - | 0.00000M | 0.00000M |
| Net income from continuing ops | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.14M |
| Net income applicable to common shares | 5522.00M | 3008.00M | 4758.00M | 2166.00M | 1472.00M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 35289.00M | 30278.00M | 24627.00M | 21143.00M | 15144.00M |
| Intangible assets | 101.00M | 146.00M | 254.00M | 338.00M | 470.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | - | - | - | 10398.00M |
| Total liab | 3679.00M | 2837.00M | 2431.00M | 2022.00M | 1096.00M |
| Total stockholder equity | 31610.00M | 27441.00M | 22196.00M | 19121.00M | 14048.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 54.00M | 1716.00M | 1130.00M | 1185.00M | 912.00M |
| Common stock | 66.00M | 66.00M | 66.00M | 66.00M | 65.00M |
| Capital stock | 66.00M | 66.00M | 66.00M | 66.00M | 65.00M |
| Retained earnings | 19023.00M | 14968.00M | 10020.00M | 7107.00M | 2130.00M |
| Other liab | - | 491.00M | 500.00M | 492.00M | 3.00M |
| Good will | - | - | - | - | 0.00000M |
| Other assets | - | 300.00M | 291.00M | 197.00M | 150.00M |
| Cash | 14867.00M | 9893.00M | 8957.00M | 7260.00M | 3552.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 2484.00M | 1823.00M | 1568.00M | 1253.00M | 938.00M |
| Current deferred revenue | 33.00M | 33.00M | 26.00M | 26.00M | - |
| Net debt | -14097.00000M | -9296.00000M | -8532.00000M | -6941.00000M | -3371.00000M |
| Short term debt | 90.00M | 74.00M | 62.00M | 42.00M | 26.00M |
| Short long term debt | - | - | - | - | 0.00000M |
| Short long term debt total | 770.00M | 597.00M | 425.00M | 319.00M | 181.00M |
| Other stockholder equity | 12461.00M | 12309.00M | 12029.00M | 11894.00M | 11755.00M |
| Property plant equipment | - | 1322.00M | 975.00M | 736.00M | 414.00M |
| Total current assets | 33139.00M | 28377.00M | 22736.00M | 18791.00M | 13961.00M |
| Long term investments | 134.00M | 133.00M | 371.00M | 1081.00M | 149.00M |
| Net tangible assets | - | 27295.00M | 21942.00M | 18783.00M | 13578.00M |
| Short term investments | 13268.00M | 12431.00M | 10381.00M | 8819.00M | 7419.00M |
| Net receivables | 4947.00M | 6053.00M | 3398.00M | 2712.00M | 2990.00M |
| Long term debt | - | - | - | - | 0.00000M |
| Inventory | 57.00M | - | - | - | -10398.00000M |
| Accounts payable | 2307.00M | - | 350.00M | - | 0.00000M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | 60.00M | 98.00M | 81.00M | 54.00M | 98.00M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | 66.00M | 65.00M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | - | 48.00M | 27.00M | 20.00M | 11.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 2150.00M | 1901.00M | 1891.00M | 2352.00M | 1183.00M |
| Capital lease obligations | 770.00M | 597.00M | 425.00M | 319.00M | 181.00M |
| Long term debt total | - | - | - | - | 155.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2761.00000M | -709.00000M | -2351.00000M | -1983.00000M | -1777.55300M |
| Change to liabilities | 283.00M | 304.00M | 681.00M | 440.00M | 134.00M |
| Total cashflows from investing activities | -2761.00000M | -961.00000M | -2351.00000M | -1983.00000M | -1778.00000M |
| Net borrowings | -73.00000M | -58.00000M | -44.00000M | -31.00000M | -31.00000M |
| Total cash from financing activities | -789.00000M | -420.00000M | 71.00M | 3660.00M | -70.90100M |
| Change to operating activities | - | -770.00000M | -770.00000M | -770.00000M | -770.00000M |
| Net income | 7035.00M | 3983.00M | 5904.00M | 2859.00M | 1611.97M |
| Change in cash | 936.00M | 1697.00M | 3708.00M | 3019.00M | -814.63800M |
| Begin period cash flow | 8957.00M | 7260.00M | 3552.00M | 533.00M | 1347.55M |
| End period cash flow | 9893.00M | 8957.00M | 7260.00M | 3552.00M | 532.91M |
| Total cash from operating activities | 3912.00M | 2228.00M | 6433.00M | 1326.00M | 1014.79M |
| Issuance of capital stock | - | 0.00000M | 0.00000M | 3873.00M | 0.31M |
| Depreciation | 362.00M | 248.00M | 259.00M | 139.00M | 87.60M |
| Other cashflows from investing activities | - | - | - | -1872.00000M | -1300.18700M |
| Dividends paid | - | - | - | 0.00000M | 0.00000M |
| Change to inventory | - | - | - | 0.00000M | 0.00000M |
| Change to account receivables | -2213.00000M | -1074.00000M | 306.00M | -0.00006M | -0.00004M |
| Sale purchase of stock | -908.00000M | -447.00000M | 0.00000M | 0.00000M | -146.17500M |
| Other cashflows from financing activities | 192.00M | 85.00M | 115.00M | -182.00000M | 74.96M |
| Change to netincome | -78.00000M | -314.00000M | 422.00M | 211.00M | 89.00M |
| Capital expenditures | 317.00M | 252.00M | 307.00M | 111.00M | 477.37M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -1930.00000M | -770.00000M | 987.00M | -1218.00000M | -634.37200M |
| Stock based compensation | 439.00M | 310.00M | 200.00M | 147.00M | 90.76M |
| Other non cash items | -1994.00000M | -997.00000M | 409.00M | -216.00000M | -231.68800M |
| Free cash flow | 3595.00M | 1976.00M | 6126.00M | 1215.00M | 537.42M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GMAB Genmab AS |
0.05 0.25% | 20.19 | 23.34 | 26.04 | 1.17 | 4.18 | 0.94 | 2.58 |
| NVO Novo Nordisk A/S |
-2.26 2.13% | 103.70 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
-1.68 1.57% | 105.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-55.6951 12.45% | 391.80 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-4.445 0.62% | 710.17 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Carl Jacobsens Vej 30, Copenhagen, Denmark, 2500
| Name | Title | Year Born |
|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO | 1961 |
| Mr. Anthony Pagano | Exec. VP & CFO | 1978 |
| Mr. Anthony Mancini | Exec. VP & COO | 1971 |
| Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer | 1958 |
| Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines | 1973 |
| Dr. Mijke Zachariasse Ph.D. | Director of Protein Production & Chemist and Non-Independent Director | 1974 |
| Dr. Rima Bawarshi Nassar Ph.D. | VP, Head of Global Regulatory Affairs ? Oncology & Non-Independent Director | 1953 |
| Mr. Peter Ros | Sr. Director of Fin. & Accounting | NA |
| Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations | NA |
| Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer | 1961 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...